News & Updates

GI cancer patients could continue therapy during COVID-19 pandemic

10 Mar 2021 by

Results of a single-centre study in the UK have suggested that patients receiving systemic anticancer therapy for gastrointestinal (GI) cancers could continue their treatment during the COVID-19 pandemic.

GI cancer patients could continue therapy during COVID-19 pandemic

10 Mar 2021

Chemo continues to benefit UTUC patients, updated POUT analysis shows

10 Mar 2021 by

In an updated analysis of the phase III POUT* trial presented at ASCO GU 2021, peri-operative chemotherapy continued to improve disease-free survival (DFS) compared with surveillance in patients with upper tract urothelial cancer (UTUC).

Chemo continues to benefit UTUC patients, updated POUT analysis shows

10 Mar 2021

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

10 Mar 2021 by

First-line treatment with nivolumab plus cabozantinib (NIVO+CABO) led to significantly better patient-reported quality of life (QoL) outcomes compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to an exploratory analysis of the CheckMate 9ER* trial presented at ASCO GU 2021.

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

10 Mar 2021

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

09 Mar 2021 by

Enfortumab vedotin improved overall survival (OS) compared with chemotherapy in patients with previously treated, locally advanced or metastatic urothelial carcinoma (UC), according to interim results of the phase III EV-301 study.

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

09 Mar 2021

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma

09 Mar 2021

In patients with regionally advanced melanoma, concurrent administration of ipilimumab and radiation therapy is safe and beneficial, producing high response rates and converting unresectable disease to operable, as shown in a study.

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma

09 Mar 2021

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

09 Mar 2021 by

Cabozantinib reduces the risk of disease progression or death by 40 percent compared with the current standard sunitinib in patients with metastatic papillary renal cell carcinoma (mPRCC) – a primary malignant tumour of the renal tubular epithelium – in the phase 2 SWOG 1500 study.

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

09 Mar 2021

CAR T-cell therapy makes it to the clinic in Hong Kong

09 Mar 2021 by

Haematologists from the University of Hong Kong (HKU) have reported initial success with chimeric antigen receptor (CAR) T-cell therapy, treating the first patient in Hong Kong in May 2020 in a global lymphoma trial and another leukaemia patient in October 2020 in a real-world clinical practice setting.

CAR T-cell therapy makes it to the clinic in Hong Kong

09 Mar 2021

N-803 shows promise for BCG-unresponsive NMIBC carcinoma in situ

08 Mar 2021 by

Intravesical administration of the IL-15RαFc* superagonist N-803 with BCG** demonstrated a strong efficacy and an excellent safety and tolerability profile in patients with BCG-unresponsive high-grade NMIBC*** carcinoma in situ, according to an interim analysis presented at ASCO GU 2021.

N-803 shows promise for BCG-unresponsive NMIBC carcinoma in situ

08 Mar 2021

ATTRACTION-3: Nivolumab significantly improves OS in advanced ESCC

08 Mar 2021 by

Treatment with nivolumab led to significantly improved overall survival (OS) in patients with advanced oesophageal squamous cell carcinoma (ESCC), according to updated results of the ATTRACTION-3* study presented at ASCO GI 2021.

ATTRACTION-3: Nivolumab significantly improves OS in advanced ESCC

08 Mar 2021

Lenvatinib + pembrolizumab shows CLEAR survival benefit over sunitinib in advanced RCC

06 Mar 2021 by

The combination therapy of lenvatinib plus pembrolizumab significantly improves survival outcomes compared with the standard-of-care treatment of sunitinib in the first-line setting for advanced renal cell carcinoma (RCC), according to the CLEAR* study presented at the 2021 ASCO GU Cancer Symposium.

Lenvatinib + pembrolizumab shows CLEAR survival benefit over sunitinib in advanced RCC

06 Mar 2021

News & Updates

Filter by Specialty:

Specialty:

GI cancer patients could continue therapy during COVID-19 pandemic

GI cancer patients could continue therapy during COVID-19 pandemic

Chemo continues to benefit UTUC patients, updated POUT analysis shows

Chemo continues to benefit UTUC patients, updated POUT analysis shows

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

CAR T-cell therapy makes it to the clinic in Hong Kong

CAR T-cell therapy makes it to the clinic in Hong Kong

N-803 shows promise for BCG-unresponsive NMIBC carcinoma in situ

N-803 shows promise for BCG-unresponsive NMIBC carcinoma in situ

ATTRACTION-3: Nivolumab significantly improves OS in advanced ESCC

ATTRACTION-3: Nivolumab significantly improves OS in advanced ESCC

Lenvatinib + pembrolizumab shows CLEAR survival benefit over sunitinib in advanced RCC

Lenvatinib + pembrolizumab shows CLEAR survival benefit over sunitinib in advanced RCC